Aamir Malik, Pfizer chief business innovation officer
As dust settles on the Arena buyout, Pfizer exec suggests company will pursue a more aggressive M&A strategy
Pfizer made a big splash in the M&A space Monday, announcing a $6.7 billion buyout of Arena Pharmaceuticals to chase Bristol Myers Squibb in the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
